Prime Medicine, Inc. (PRME) is a Healthcare stock trading at $3.23 (as of 2026-06-18), with a market capitalization of $641.19M and a trailing P/E of -2.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.